Loading...

Pluristem Therapeutics Inc.

PSTI•NASDAQ
Healthcare
Biotechnology
$1.00
$-0.03(-2.91%)

Pluristem Therapeutics Inc. (PSTI) Stock Overview

Explore Pluristem Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap40.8M
P/E Ratio-0.56
EPS (TTM)$-1.46
ROE-0.88%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.59

PSTI Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Pluristem Therapeutics Inc. (PSTI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.59.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.56 and a market capitalization of 40.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for PSTIStats details for PSTI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PSTIAnalyst Recommendations details for PSTI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

CEO

Yaky Yanay

Employees

153

Headquarters

Matam Advanced Technology Park, Building No. 5, Haifa

Founded

2007

Frequently Asked Questions

;